| 摘要 |
PURPOSE: A pharmaceutical composition of amniotic mesenchymal stem cells (AMMs) is provided to have excellent angiogenesis effect in an animal model of hindlimb ischemia. CONSTITUTION: A method for differentiating human AMMs into vascular endothelial cells comprises the steps of: culturing the AMMs in a medium containing serum; and culturing the AMMs in a complete medium for differentiating the AMMs to vascular endothelial cells. A pharmaceutical composition for preventing and treating hindlimb ischemia, ischemic myocardial infarction, ischemic peripheral vascular disease, diabetic necrosis, diabetic peripheral vascular disease, or Buerger's disease contains a pharmaceutically effective amount of the AMMs and a pharmaceutically acceptable carrier. |
